Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06707142 · ClinicalTrials.gov registry record · Phase 1
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
A Phase 1 study of Healthy Adult Participants, sponsored by Gates Medical Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT06707142: Recruiting Phase 1 study of Healthy Adult Participants, sponsored by Gates Medical Research Institute.
NCT06707142 is a Phase 1 study of Healthy Adult Participants that is actively recruiting participants, run by Gates Medical Research Institute. The registered enrollment target is 124 participants, above the 49-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06707142, a Phase 1 study of Healthy Adult Participants, is actively recruiting participants, sponsored by Gates Medical Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (MAD) cohorts and tablet formulation evaluation (Part 2, Cohort 4).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TBD11
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
What NCT06707142 shows while recruiting
NCT06707142 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 49-participant average among 4 other Healthy Adult Participants trials with a reported enrollment target (153% higher).
The record links to 1 condition, with Healthy Adult Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06707142 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT06707142 about?
NCT06707142 is a clinical study titled "A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11". This is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (M...
What is the current status of trial NCT06707142?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2024-12-05. Estimated completion is 2026-02.
What conditions does trial NCT06707142 study?
This clinical trial studies the following conditions: Healthy Adult Participants.
What interventions are being tested in trial NCT06707142?
The interventions under investigation include: Placebo (DRUG), TBD11 (DRUG).
Who is sponsoring clinical trial NCT06707142?
This trial is sponsored by Gates Medical Research Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06707142 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
COMPLETED · Phase 1
-
Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI